TRVI - Trevi Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

TRVI is currently covered by 4 analysts with an average price target of $17.61. This is a potential upside of $11.56 (191.07%) from yesterday's end of day stock price of $6.05.

Trevi Therapeutics's activity chart (see below) currently has 5 price targets and 31 ratings on display. The stock rating distribution of TRVI is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 21.33% with an average time for these price targets to be met of 118.4 days.

Highest price target for TRVI is $24, Lowest price target is $12.5, average price target is $19.38.

Most recent stock forecast was given by SERGE BELANGER from NEEDHAM on 19-Mar-2025. First documented stock forecast 03-Jun-2019.

Best performing analysts who are covering TRVI - Trevi Therapeutics:

Mayank Mamtani Oren Livnat Serge Belanger Leland Gershell Jason Kolbert

Currently out of the existing stock ratings of TRVI, 25 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$24

$17.95 (296.69%)

$25

18 days ago
(19-Mar-2025)

0/14 (0%)

$17.19 (252.42%)

Buy

$21

$14.95 (247.11%)

$21

18 days ago
(19-Mar-2025)

0/5 (0%)

$14.19 (208.37%)

Buy

$12.5

$6.45 (106.61%)

$12.5

18 days ago
(19-Mar-2025)

2/5 (40%)

$5.69 (83.55%)

166

Buy

$20

$13.95 (230.58%)

$6

18 days ago
(19-Mar-2025)

2/3 (66.67%)

$13.19 (193.69%)

426

Buy

$10

$5.93 (145.70%)

$10

2 years 9 months 8 days ago
(29-Jun-2022)

0/2 (0%)

$7.55 (308.16%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is TRVI (Trevi Therapeutics) average time for price targets to be met?

On average it took 118.4 days on average for the stock forecasts to be realized with a an average price target met ratio 21.33

Which analyst has the current highest performing score on TRVI (Trevi Therapeutics) with a proven track record?

MAYANK MAMTANI

Which analyst has the current lower performing score on TRVI (Trevi Therapeutics) with a proven track record?

JASON KOLBERT

Which analyst has the most public recommendations on TRVI (Trevi Therapeutics)?

Mayank Mamtani works at B. RILEY and has 8 price targets and 5 ratings on TRVI

Which analyst is the currently most bullish on TRVI (Trevi Therapeutics)?

Serge Belanger with highest potential upside - $17.95

Which analyst is the currently most reserved on TRVI (Trevi Therapeutics)?

Leland Gershell with lowest potential downside - $5.93

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?